For the nine months ended September 30, 2022, we had net income of $6,416,596, which resulted from a gain on the change in fair value of warrant liabilities of $7,685,022, a gain on the waiver of deferred underwriting commission by the underwriter of $198,671, and dividend income on the Trust Account of $503,468, offset in part by operating and formation costs of $1,970,565.
For the period from January 15, 2021 (inception) through September 30, 2021, we had net income of $3,070,957, which resulted from a gain on the change in fair value of warrant liabilities of $4,236,313 and interest income on the Trust Account of $2,739, offset in part by operating and formation costs of $797,682, and expensed offering costs of $370,413.
Liquidity, Capital Resources, and Going Concern
On May 21, 2021, the Company consummated the Initial Public Offering of 14,375,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units sold, the “Public Shares”), including 1,875,000 Units that were issued pursuant to the underwriters’ exercise of their over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $143,750,000. Simultaneously with the closing of the Initial Public Offering, we completed the private sale of 4,456,250 warrants to Aries Acquisition Partners, Ltd. at a purchase price of $1.00 per warrant (the “Private Placement Warrants”), generating gross proceeds of $4,456,250. A total of $146,768,750 from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”).
For the nine months ended September 30, 2022, net cash used in operating activities was $700,396, which was due to non-cash adjustments to net income related to the gain on the change in fair value of warrant liabilities of $7,685,022, dividend income on investments held in the Trust Account of $503,468 and non-cash adjustments to net income related to the gain on the waiver of deferred underwriting commissions by the underwriter of $198,671, partially offset by our net income of $6,416,596 and changes in working capital of $1,270,169.
For the period from January 15, 2021 (inception) through September 30, 2021, net cash used in operating activities was $972,453, which was due to non-cash adjustments to net income related to the gain on change in fair value of warrant liabilities of $4,236,313, changes in working capital of $174,772, and interest income on investments held in the Trust Account of $2,739, partially offset by our net income of $3,070,957 and expensed offering costs of $370,414.
For the nine months ended September 30, 2022, net cash used in investing activities was $122,040,928, which resulted in cash withdrawn from the Trust Account for payment to redeeming shareholders of $123,279,777, partially offset by cash deposited into the Trust Account of $1,238,849.
For the period from January 15, 2021 (inception) through September 30, 2021, net cash used in investing activities of $145,187,500 was the result of the amount of net proceeds from the Initial Public Offering and the private placement sale of warrants being deposited into the Trust Account.
For the nine months ended September 30, 2022, net cash provided by financing activities was $121,570,928, which resulted from payments to redeeming shareholders of $123,279,777, partially offset by proceeds from the promissory notes of $1,708,849.
Net cash provided by financing activities for the period from January 15, 2021 (inception) through September 30, 2021 of $146,977,284 was comprised of $143,031,250 in proceeds from the issuance of Units in the Initial Public Offering net of underwriter’s discount paid, $4,456,250 in proceeds from the issuance of warrants in a private placement, and proceeds from the issuance of a promissory note to our Sponsor of $129,886, offset in part by the payment of offering costs of $510,216 associated with the Initial Public Offering and repayment of the outstanding balance on the promissory note to our Sponsor of $129,886.